Bei Wen (keverprazan) / Carephar Pharma, Fosun Pharma - LARVOL DELTA

Comparative effectiveness of genotype-guided and empirical bismuth-containing quadruple therapy for Helicobacter pylori eradication: a retrospective study. (PubMed, Front Pharmacol) - "All regimens comprised bismuth potassium citrate 2.6 g, a proton pump inhibitor (PPI, esomeprazole 20 mg or ilaprazole 5 mg) or a potassium-competitive acid blocker (P-CAB, keverprazan 20 mg or tegoprazan 50 mg), and antibiotics selected from amoxicillin, clarithromycin, levofloxacin, furazolidone, tetracycline, metronidazole, or doxycycline. Dual clarithromycin and levofloxacin resistance and alcohol consumption remained key determinants of treatment failure even with genotype-guided therapy. However, the precision of estimates for single-drug resistance subgroups was limited by small sample sizes and should be interpreted cautiously."

HEOR • Journal • Retrospective data • Addiction (Opioid and Alcohol) • Infectious Disease

KEVERPRAZAN-AMOXICILLIN VERSUS VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, PROSPECTIVE, RANDOMIZED STUDY (UEGW 2026) - No abstract available

Clinical • Infectious Disease

COMPARISON OF KEVERPRAZAN-BASED VERSUS ESOMEPRAZOLE-BASED DUAL THERAPY FOR INITIAL TREATMENT OF HELICOBACTER PYLORI INFECTION: A PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED TRIAL (UEGW 2026) - No abstract available

Clinical • Infectious Disease

COMPARATIVE EFFICACY AND SAFETY OF KEVERPRAZAN-AMOXICILLIN DUAL THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, RANDOMIZED CONTROLLED STUDY (UEGW 2026) - No abstract available

Clinical • Infectious Disease

KEVERPRAZAN FOR DUODENAL ULCER, EROSIVE OESOPHAGITIS, AND HELICOBACTER PYLORI ERADICATION: A SYSTEMATIC REVIEW WITH SUBGROUP ANALYSIS (UEGW 2026) - No abstract available

Review • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Jiangsu Carephar Pharmaceutical Co., Ltd. | Enrolling by invitation ➔ Completed

Trial completion • Gastrointestinal Disorder

THE EFFICACY AND SAFETY OF KEVERPRAZAN (H008) IN THE TREATMENT OF DUODENAL ULCER: A MULTICENTERED, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL TRIAL IN CHINA (UEGW 2022) - "Keverprazan 20 mg was not inferior to lansoprazole 30 mg once daily for healing of DU with a good safety profile."

Clinical • Peptic Ulcer

Fertility and early embryonic development toxicity and toxicokinetic study of KFP-H008 in Sprague-Dawley rats. (PubMed, Birth Defects Res) - "Overall, the NOAEL of KFP-H008 was considered to be 45 mg/kg in both genders and the TK study shows that exposure (area under the curve) of male rats was about 1,091.0 ± 530.8 μg/Lhr and to female rats was 1,030.5 ± 512.5 μg/Lhr. Administration of KFP-H008although reaches the reproductive organs, it demonstrated no significant effects on reproductive organs, it did not affect mating, fertility, pregnancy, growth, or morphologic development."

Journal • Preclinical